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Abstract: Carfilzomib is a selective, irreversible proteasome inhibitor, initially approved in the
US in 2012 as single-agent therapy for relapsed and refractory multiple myeloma. Numerous
Phase II studies have evaluated carfilzomib in the relapsed and refractory as well as the newly
diagnosed setting, and Phase III studies are entering their final analysis. Data continue to grow
to support its use as both single-agent therapy and in combination with immunomodulatory and
other novel agents. This review discusses the role of carfilzomib in the treatment of multiple
myeloma. Its mechanism of action, pharmacokinetics, and role in clinical management will
be reviewed.
Keywords: relapsed and refractory, targeted therapy, proteasome inhibitor, novel agents
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Multiple myeloma (MM), a clonal plasma cell disorder, is the second-most common
hematological malignancy. Incidence in the US is estimated at 24,000 people annually,
with 11,000 deaths expected in 2014.1 Significant recent progress in the treatment of
MM has led to clinical improvements in progression-free survival (PFS) and overall
survival (OS).
While MM was once a rapidly progressive disease, initial progress was made
with the introduction of melphalan and steroid combination therapy in the 1960s. The
subsequent advent of autologous stem cell transplantation (ASCT) and novel agents,
including the proteasome inhibitors and immunomodulatory agents, further extended
OS. Continued progress is ongoing, with Surveillance Epidemiology and End Results
(SEER) data showing death rates falling 1.7% per year over the past decade.
The upfront treatment of patients with novel agents has now become the standard of
care for induction therapy in transplant-eligible and -ineligible patients.2 Nevertheless,
responses are temporary and relapse is nearly universal. With disease progression,
the majority of patients become resistant to prior lines of therapy, underlining the
importance of new and effective treatments.3
A potent and highly selective proteasome inhibitor, carfilzomib is an effective and
tolerable therapy for patients with MM. In 2012, it was granted fast-track approval
by the US Food and Drug Administration for the treatment of MM patients who have
received at least two prior therapies, including bortezomib and an immunomodulatory agent, and have demonstrated disease progression on or within 60 days of the
completion of the last therapy. The data supporting its utility and safety continue to
grow as further studies investigate its use in the up-front, relapsed and refractory, and
combination-therapy settings.
23
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Proteasome pathway
and carfilzomib
The ubiquitin–proteasome pathway is a crucial cellular
housekeeping pathway responsible for the degradation
and removal of regulatory cellular proteins. It has a central
role in the regulation of cell-cycle progression and cellular
senescence. Targeted proteins are enzymatically polyubiquitinated, marking them for degradation by the 26S proteasome.
The 26S proteasome consists of two 19S regulatory complexes, capping a central 20S proteolytic core. Ubiquitinated
proteins are guided into the 20S core after recognition by a
19S complex. Major catalytic activities of the 20S core include
a chymotrypsin-like (ChT-L) activity found in the β5 subunit,
a trypsin-like activity in the β2 subunit, and a caspase-like
activity in the β1 subunit.4 ChT-L activity has been shown to
be the rate-limiting step of proteolysis in vitro and in vivo.5
Carfilzomib is an irreversible, epoxyketone proteasome
inhibitor that specifically targets the ChT-L activity of the
20S proteasome.6 Epoxyketones are derivatives of epoxomicin, a natural product isolated from actinomycetes that
forms an irreversible, selective, and highly specific adduct
with the N-terminal threonine of the ChT-L β5 subunit of
the 20S proteolytic core.7
Compared with the reversible inhibitor bortezomib,
carfilzomib is a covalent inhibitor with greater in vitro
selectivity and less off-target activity.8 Furthermore, it has
been shown to be active in cell lines that are resistant to
bortezomib and other available therapies.6 This enhanced
inhibition of proteasome function leads to the accumulation
of proteins targeted for degradation and subsequent cellular
apoptosis.9,10

Preclinical studies
Due to the superior specificity of carfilzomib when compared
to prior proteasome inhibitors, it was expected that preclinical tests would show improved proteasome inhibition and
enhanced antitumor activity. Initial tests utilizing purified
extracts of human 20S enzyme showed carfilzomib to have a
dose-dependent inhibition of ChT-L proteolytic activity. This
dose-dependent inhibition persisted when investigations were
pursued utilizing intact mammalian cells.9
Most cell culture-based studies evaluating cytotoxicity
of prior proteasome inhibitors showed effective proapoptotic
effects, but utilized long incubation times (24–72 hours)
that were unrealistic mirrors of in vivo activity. Carfilzomib,
however, showed impressive proteasome inhibition and cytotoxicity in hematologic tumor cell lines with short incubation
times (1 hour).9
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Furthermore, activity in MM cell lines showed effective
induction of apoptosis in cultured tumor cells, including
significant activity in bortezomib-resistant cell lines.11
Comparisons between carfilzomib and bortezomib performed
via tumor xenografts in immunocompromised mouse models
showed improved efficacy over bortezomib, with carfilzomib
inducing significant reductions in tumor-implant burden, and
minimal toxicity.16

Pharmacokinetics
and pharmacodynamics
Key pharmacokinetic and pharmacodynamic studies
were performed in two Phase I studies: PX-171-001 and
PX-171-002. These trials found that carfilzomib is rapidly
metabolized to inactive metabolites, with minimal reliance
on the cytochrome P450 pathway. The mean elimination
half-life was generally less than 30 minutes. Observed rates
of clearance exceeded hepatic blood flow, suggesting that
carfilzomib is largely cleared extrahepatically, possibly by
multiple pathways.12–14
There was wide variation in both intra- and interpatient
carfilzomib plasma concentrations, possibly due to differences in administration and monitoring. Both the maximum
concentration and area under the curve increased with dose,
but not in a dose-proportional manner. The volume of distribution at a steady state suggested wide tissue distribution
in both studies.12–14
Pharmacodynamic studies evaluated inhibition of the
20S ChT-L proteasome activity in both whole blood and
peripheral blood mononuclear cells (PBMCs). Samples taken
1 hour after dosing with 15 mg/m2 revealed more than 70%
inhibition in PBMCs. At 27 mg/m2, approximately 90% inhibition was seen in PBMCs. In PX-171-002, which evaluated
dosing on 2 consecutive days for 3 weeks of a 4-week cycle,
proteasome inhibition after the second dose was equivalent to
or greater than that seen with the first dose. In PX-171-001,
which evaluated 5-day consecutive dosing on 2-week cycles,
proteasome inhibition was observed at greater than 90% on
the 5th day of dosing. Recovery of proteasome activity was
seen in PBMCs prior to the second cycle of dosing on both
schedules.12–14

Use in relapsed and refractory
multiple myeloma
Single agent
Approval for carfilzomib was based on the results of the
Phase IIB PX-171-003-A1 trial, enrolling relapsed and refractory MM (RRMM) patients who had been previously treated
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with both bortezomib and an immunomodulatory drug. With
257 evaluable patients, this trial examined carfilzomib’s efficacy
in a heavily pretreated population (median of five prior thera
pies) that was highly bortezomib-resistant (74%). Carfilzomib
was found to have an overall response rate (ORR) of 23.7%,
improving to 37% when minimal responses (MRs) were
included. Duration of response was 7.8 months, with median
time-to-progression of 3.9 months and an OS of 15.6 months.
Treatment-related grade 3–4 adverse events (AEs) were primarily fatigue (7.5%), acute kidney injury (3.4%), and dyspnea
(3.4%). Hematologic grade 3–4 AEs included anemia (24%)
and thrombocytopenia (29%).15 Given its tolerable safety profile and proven efficacy, carfilzomib was granted a fast-track
approval following the results of this pivotal Phase II study.
Prior to PX-171-003-A1, initial pharmacokinetics
and toxicity were examined in two Phase I clinical trials:
PX-171-001 and PX-171-002. The maximum tolerated dose
(MTD) in PX-171-001 was 15 mg/m2 (carfilzomib dosed on
days 1–5 every 14 days), and in PX-171-002 the MTD was
not reached with patients receiving 20 mg/m2 in week 1 and
27 mg/m2 in subsequent weeks (dosing on days 1, 2, 8, 9,
15, and 16 of 28-day cycles). In PX-171-001, grade 3 febrile
neutropenia and grade 4 thrombocytopenia were observed,
establishing the MTD at 15 mg/m2. PX-171-002 used an
alternative dosing strategy, with grade 3–4 AEs primarily
consisting of anemia, thrombocytopenia, and fatigue. Due to
its improved tolerability, PX-171-002 set the standard dose
regimen for further investigations.12,13
In the pivotal PX-171-003-A1 study, doses of carfilzomib
were administered at 20–27 mg/m2, with each dose given
over a period of up to 10 minutes. Building on animal data
suggesting improved tolerability with prolonged infusion
times, Papadopoulos et al investigated an alternative dosing
strategy in a subsequent Phase I study. In this trial, 33 patients
were assigned to receive carfilzomib over 30 minutes at doses
escalating from 20 mg/m2 through 70 mg/m2. MTD was
defined as 56 mg/m2, with dose-limiting toxicities of renal
tubular necrosis and proteinuria (grade 3) in two patients at
70 mg/m2. The ORR was 50% for patients treated at 56 mg/m2
(12 patients). The addition of low-dose dexamethasone (40 mg
weekly); increased the ORR to 55% among 22 patients treated
at 45 or 56 mg/m2. Toxicities were minimal, and largely consisted of grade 1–2 anemia and thrombocytopenia. Peripheral
neuropathy was rare. This confirmed the apparent safety and
efficacy of a dose-escalated regimen. Investigation into optimal dosing continues.16
Further studies examined carf ilzomib’s role in
bortezomib-naïve patients. In the Phase II PX-171-004 study,
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single-agent carfilzomib was evaluated in 165 patients with
relapsed and/or refractory MM who had received one to three
previous lines of therapy. A total of 129 patients with refractory, bortezomib-naïve MM were assigned to successive treatment cohorts. Initial dosing with 20 mg/m2 was subsequently
dose-escalated to 27 mg/m2. The ORR was found to be 42%
for patients treated with 20 mg/m2 over 12 cycles, and 52%
for patients treated with 20 mg/m2 for one cycle followed by
27 mg/m2 for cycles 2–12. When MRs were included, the
ORR increased to 59% for the lower-dose cohort and 64% for
the higher-dose cohort. Time to progression was not reached
in the 27 mg/m2 group versus 8.3 months in the 20 mg/m2
group. Treatment-emergent AEs of all grades included fatigue
(62%), dyspnea (38.8%), diarrhea (31%), anemia (41.9%),
and thrombocytopenia (30.2%). Peripheral neuropathy was
rare (17.1%) and did not limit treatment.17
Results from pivotal Phase III studies are in the early
stages of reporting data evaluating carfilzomib’s efficacy. In
the FOCUS trial, a randomized, controlled, Phase III trial,
315 patients with RRMM were enrolled across several international centers. Patients were randomly allocated to one of
two treatment regimens: single-agent carfilzomib versus a
steroid optionally combined with oral cyclophosphamide.
The majority of patients allocated to steroids received
cyclophosphamide. Enrolled patients had been heavily pretreated with a median of five prior lines of therapy. Preliminary
reports have revealed that there was no statistically significant
OS difference between the two arms. As of yet, no actual
numbers for OS or PFS have been reported in the literature,
and full details are pending final publication. Safety data
have likewise not yet been released, but reportedly the rate of
cardiac events was consistent with prior cohorts.18

Combination therapy
Given its limited off-target effects and favorable safety profile, carfilzomib is an attractive agent for use in combination
treatment.
The CHAMPION-1 trial is a Phase I, dose-escalation
study investigating weekly carfilzomib in combination with
dexamethasone for RRMM patients. Patients were treated
with carfilzomib on days 1, 8, and 15 of each 28-day cycle
with an initial dose of 20 mg/m2 and subsequent cycles
starting at 45 mg/m2, with dose-escalation cohorts of 56, 70,
and 88 mg/m2. Dexamethasone was given weekly on days
1, 8, 15, and 22 for the first eight cycles, after which day
22 dexamethasone was omitted. A total of 18 patients were
enrolled, with two dose-limiting toxicities observed at the
88 mg/m2 dose level. The ORR was 67% with four complete
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responses (CR), one very good partial response (VGPR), five
partial responses (PR) and three minimal responses (MR).
Overall, the weekly dosing at 70 mg/m2 demonstrated a comparable half-life and higher area under the curve per cycle
compared with the currently approved twice-weekly dosing
regimen. More data are necessary to confirm this MTD and
response data. Safety data were significant for two patients
with grade 3 acute kidney injury, as well as one patient each
with grade 3 dyspnea, pneumonia, and hyponatremia.19
Further examining the role of carfilzomib in combination
with dexamethasone, Lendvai et al evaluated the efficacy of
this combination in a small cohort of a Phase II study. In this
trial, patients with RRMM failing to achieve at least a PR
after two cycles of carfilzomib were assigned to dexamethasone in addition to carfilzomib. A total of 34 patients were
treated with eleven requiring the addition of dexamethasone.
Additional responses were limited, with four of the eleven
patients eventually achieving a PR and continuing treatment
for an average of an additional 4.5 cycles.20
The Phase IB/II PX-171-006 study examined the combination of carfilzomib, lenalidomide, and dexamethasone in
patients with relapsed or progressive MM with one to three
lines of previous therapy. MTD was determined for the combination in the Phase IB portion (carfilzomib 20/27 mg/m2,
lenalidomide 25 mg, and dexamethasone 40 mg). Following a Phase II expansion, there were 84 total patients, 52 of
whom were treated at the MTD. At a median of 24.4 months
of follow-up, the ORR was 69% in the overall population and
76.9% in the patients treated at the MTD. Median PFS was
reported at 11.8 months, with a median duration of response
of 18.8 months. Grade 3–4 AEs included lymphopenia
(48.1%), neutropenia (32.7%), fatigue (7.1%), and diarrhea
(6%). Grade 3–4 dyspnea and peripheral neuropathy were
rare, at 1.2% each.21,22
Building on the role of carfilzomib in combination with
immunomodulatory agents, Shah et al evaluated the combination of carfilzomib and pomalidomide with dexamethasone
(Car-Pom-d). In a Phase I/II study evaluating a heavily
pretreated population of RRMM patients, the Car-Pom-d
regimen was well tolerated and achieved a high response
rate (ORR of 64%, $MR rate of 81%). Of the 72 enrolled
patients, all were lenalidomide-refractory and 87% had prior
bortezomib exposure.23
Additional novel combinations utilizing carfilzomib are
under investigation in RRMM. A Phase I study has been
presented evaluating ARRY-520, a kinesin spindle protein
inhibitor, in combination with carfilzomib in patients with
RRMM. ARRY-520 was administered intravenously on days
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1, 2, 15, and 16 in combination with carfilzomib (days 1, 2,
8, 9, 15, and 16) on 28-day cycles. Of a total of 20 patients,
19 were evaluable for outcomes. The ORR ($MR) was 58%,
with one patient having a near-CR (nCR) and six patients
with a PR. Toxicity was limited and the combination was well
tolerated, with six episodes of pneumonia and one episode
each of febrile neutropenia and bacteremia.24
Early Phase III data are also in preliminary stages for
combination therapy. The ASPIRE trial is a randomized,
multicenter, open-label Phase III trial assessing the differences in PFS among relapsed MM patients enrolled onto
treatment with carfilzomib in combination with lenalidomide
and dexamethasone (KRd) compared to lenalidomide and
dexamethasone alone. Patients were treated with carfilzomib
dosed at 20 mg/m2 on days 1 and 2 of cycle 1, then 27 mg/m2
for subsequent doses. Both arms received lenalidomide at
25 mg per day for 21 days of a 28-day cycle in combination
with dexamethasone (Rd). Initial prepublication reports of a
planned interim analysis show that with a total of 792 patients
enrolled at over 100 treatment centers, the PFS for KRd was
26.3 months, a statistically significant improvement over
17.6 months for those in the Rd regimen. There was a trend
toward improvement in OS in KRd, although this was not
statistically significant at this time. Full presentation of the
trial data is still pending final publication. No new concerns
were raised by preliminary safety data, with similar rates of
AEs as seen in previous trials.25

Upfront treatment
An ongoing area of investigation, the use of carfilzomib in the
upfront setting promises to improve response rates and extend
PFS and OS. Several studies have already reported the results
of carfilzomib in the treatment of newly diagnosed MM.
In a Phase I/II study by Jakubowiak et al, both transplant-eligible and -ineligible newly diagnosed MM patients
were evaluated. Patients on this study were enrolled onto
induction therapy with carfilzomib, lenalidomide, and
dexamethasone (KRd). Patients received up to eight cycles
of induction therapy with carfilzomib dosed at 20, 27, or
36 mg/m2, lenalidomide at 25 mg, and dexamethasone at
40 mg (cycles 1–4) and 20 mg (cycles 5–8). Transplanteligible patients were able to move to transplant (seven
proceeded to transplant and 35 had stem cell collection
after cycle 4). Patients could continue KRd until cycle 24.
With a median follow-up of 25 months, the ORR was 98%,
with a CR rate of 64%. At 2 years, the estimated PFS was
94% and OS was 98%. Overall treatment was tolerated in
patients, with a limited number of AEs.26
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Another trial evaluating both transplant-eligible
and -ineligible patients is examining the role of carfilzomib,
clarithromycin, lenalidomide, and dexamethasone as combination therapy for newly diagnosed MM. Newly diagnosed
patients were treated with carfilzomib (days 1, 2, 8, 9, 15,
and 16 of 28-day cycles) and dexamethasone 40 mg weekly.
Treatment continued until a response plateau was achieved
(no change in M protein for two cycles). Transplant-eligible
patients proceeded to ASCT, and ineligible patients went
straight to consolidation therapy. All patients received consolidation treatment with clarithromycin 500 mg twice daily,
lenalidomide 25 mg daily on days 1–21, and dexamethasone
40 mg weekly in 28-day cycles. Consolidation continued until
a second plateau was achieved, followed by lenalidomide
maintenance (10 mg daily on days 1–21 of 28-day cycles).
Of a total of 23 evaluable patients, at 30.8 weeks of median
follow-up, the ORR was 87%, with 9% achieving a stringent CR (sCR), 39% attaining a VGPR, and 35% showing
at least a PR. A total of five patients came off therapy due
to grade 3 renal failure (two patients), grade 3 congestive
heart failure (CHF; two patients), and a grade 3 venous
thromboembolism.27
The combination of carfilzomib, lenalidomide, and dexamethasone followed by lenalidomide maintenance was investigated in newly diagnosed transplant-eligible and -ineligible
MM patients. Patients were initiated onto treatment with carfilzomib 20/36 mg/m2 (days 1, 2, 8, 9, 15, and 16), lenalidomide
(25 mg orally days 1–21), and dexamethasone (20/10 mg on
days 1, 2, 8, 9, 15, 16, 22, and 23). Patients eligible for transplant underwent stem cell collection after cycle 4. Following
eight cycles of induction, patients with at least stable disease
received up to 24 cycles of lenalidomide (10 mg on days 1–21
of 28-day cycles). A total of 41 patients were enrolled, and
after a median of nine cycles, 63% had at least a CR, 26%
had a VGPR, and 8% had a PR. With a median follow-up of
10 months, PFS was 83.3%. Minimal residual disease (MRD)
negativity was also assessed, with 100% of the 17 patients
achieving a CR also found to be negative by MRD testing.
Among those attaining at least a VGPR, 63% had evidence of
abnormal plasma cells by MRD assessment.28
The CARTHADEX trial evaluated the combination of
carfilzomib, thalidomide, and dexamethasone (CTD) for
induction and consolidation therapy in transplant-eligible
patients with newly diagnosed MM. Patients were treated
with CTD for four cycles with thalidomide 200 mg on days
1–28, dexamethasone 40 mg on days 1, 8, 15, and 22, and
carfilzomib dosed differently in three cohorts (20–45 mg/m2).
Following transplantation, patients underwent consolidation
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with four cycles of CTD. The primary end point was
VGPR after four cycles of CTD. The results of the first two
carfilzomib-dose cohorts have been reported (20/27 mg/m2
and 36 mg/m2). With a total of 70 patients included, and
median follow-up of 22 and 7 months, the ORR was 96%.
After induction therapy, 19% of patients achieved a CR
or sCR, and 60% had at least a VGPR. The CR/sCR rate
improved to 30% after ASCT and to 49% after consolidation
therapy. The PFS was 74% in the evaluated population, with
median follow-up as noted earlier. The regimen was well
tolerated, with grade 3–4 nonhematologic toxicity observed
in ,5% of patients, primarily infection and rash.29
The CYCLONE trial is a Phase I/II study evaluating carfilzomib combination therapy in newly diagnosed
t ransplant-eligible MM patients. Enrolled patients are
assigned to induction therapy with a combination of
carfilzomib (15–45 mg/m2 on days 1, 2, 8, 9, 15, and 16),
thalidomide (100 mg on days 1–28), cyclophosphamide
(300 mg/m2 on days 1, 8, and 15), and dexamethasone
(40 mg weekly). As of the most recent publication, with a
total of 54 patients, the ORR was 91%, with 18% achieving
a CR and 58% a VGPR. Minimal toxicities were reported,
with primarily grade 1 neuropathy and minimal cardiac or
pulmonary effects. With a median follow-up of 16 months,
1-year PFS was 90% and 1-year OS was 98%.30

Role in special populations
Asymptomatic patients
Given MM’s easily observable precursor state, the role of
early treatment for patients nearing a diagnosis of MM has
been an ongoing clinical question. For these asymptomatic
or “smoldering” MM patients, there have been multiple trials
evaluating the efficacy of intervention. This remains an area
of ongoing clinical investigation without clear evidence to
guide clinical practice.
Investigating the role of carfilzomib in the asymptomatic patient, Landgren et al undertook a single-arm
Phase II trial for patients with high-risk smoldering MM.
Patients were treated with carfilzomib in combination with
lenalidomide and dexamethasone, followed by 2 years of
lenalidomide maintenance therapy. High-risk smoldering MM was defined by the PETHEMA or Mayo criteria.
Carfilzomib was given in 28-day cycles at 20/36 mg/m2
on days 1, 2, 8, 9, 15, 16, 22, and 23. After eight cycles of
induction, patients with a response consistent with stable
disease or better received lenalidomide maintenance (10 mg
daily on days 1–21) for 2 years. Twelve patients were
enrolled, with an ORR of 100% (five sCRs, two CRs, two
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nCRs, and three VGPRs), with no patients progressing to
symptomatic MM during the study. Evaluation of MRD
showed six of seven patients achieving at least a CR to
be negative by MRD assessment. The most common toxicities were rash (17%), CHF (8%), dyspnea (8%), and
lymphopenia (33%). Larger clinical studies and further
follow-up are needed, but these results show impressive
response in the smoldering MM setting.31

Renal impairment
Often a defining characteristic, renal dysfunction is a common feature of MM. Its development has been associated with
worse prognosis and shortened survival, limiting the available
treatment options and often requiring dose reductions.32
To assess the safety and efficacy of carfilzomib in
patients with renal impairment, the Phase II PX-171005 trial enrolled relapsed/refractory or progressive MM
patients who had been treated with at least two prior
regimens. A total of 50 patients were enrolled and stratified by creatinine clearance (.80 mL/min, 50–80 mL/min,
30–49 mL/min, ,30 mL/min and chronic hemodialysis).
A total of 33 of these patients (66%) were refractory to
prior bortezomib therapy. Carfilzomib was given on days
1, 2, 8, 9, 15, and 16 in 28-day cycles, with the following
dose escalation: 15 mg/m2 (cycle 1), 20 mg/m2 (cycle 2), and
27 mg/m2 (cycle 3+). The primary goal was the assessment
of pharmacokinetics, with secondary outcomes including
safety, tolerability, and efficacy.33
In the final analysis, there were no differences in carfilzomib clearance or exposure among patients with impaired
renal function versus those with normal renal function. Grade
3/4 AEs were limited to anemia (28%), thrombocytopenia
(20%), lymphopenia (18%), and fatigue (14%), and were
similar among groups. The ORR was 25.5%, with a median
duration of response of 7.9 months.33
There appears to be no differences in carfilzomib clearance or exposure among patients with normal renal function
and those with renal impairment. Additionally, the safety
of carfilzomib was not influenced by the degree of baseline
renal impairment, with carfilzomib being well tolerated and
showing promising efficacy in all groups.33

Elderly and transplant-ineligible
Age is the greatest risk factor for the development of MM,
with the disease incidence increasing steadily to a peak
of more than 40 per 100,000 people in those older than
80 years.34 The accumulation of additional comorbidities with
advancing age makes this subpopulation an important area
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for active research to improve outcomes. The initial trials of
single-agent carfilzomib enrolled patients with a median age
of 63.5 years (PX-171-003-AO), 63 years (PX-171-003-A1),
and 65 years (PX-171-004), suggesting its efficacy and tolerability in an older population.15,17,35
Combination therapies including carf ilzomib
have shown encouraging tolerability and activity in
patients $65 years of age. A Phase II study by Bringhen
et al evaluated the efficacy and safety of the combination
of carfilzomib, cyclophosphamide, and dexamethasone in
elderly patients ($65 years of age) or those ineligible for
ASCT. A total of 58 patients were enrolled and received
this combination for up to nine cycles, followed by maintenance single-agent carfilzomib. Maintenance continued
until progression or intolerance. Following a median of
nine cycles of induction (range 1–9), a total of 20% of
patients achieved an sCR and 49% had attained an nCR.
The ORR was excellent, with 95% of patients with at least
a PR and 71% with a VGPR. With a median follow-up of
18 months, the 2-year PFS was 76% and the OS rate was
87%. The regimen had an acceptable safety profile in this
population of older, transplant-ineligible patients. The
most frequent reported toxicity was fever (32%), with
peripheral neuropathy being rare (8%) and relatively mild
(grade 1–2).36
A separate Phase I/II study by Touzeau et al examined
the role of carfilzomib plus melphalan and prednisone
in elderly patients with newly diagnosed MM. A total of
24 patients .65 years of age were enrolled in the Phase I
trial and treated with carfilzomib (20 mg/m2 with escalation
to 45 mg/m2), melphalan 9 mg/m2, and prednisone 60 mg/m2.
MTD was 36 mg/m2, and the subsequent Phase II trial
enrolled 45 additional patients for a total of 69 patients. ORR
was 89%, and at a median follow-up of 12 months, projected
2-year OS was 89.9%. Carfilzomib plus melphalan and
prednisone was well tolerated without significant peripheral
neuropathy, and dosing at 40 mg/m2 was limited by grade
3–4 fever and hypotension.37
In a subgroup analysis of a Phase I/II study by Jakubowiak
et al, the efficacy of KRd was evaluated in elderly ($65 years
of age) newly diagnosed MM patients. A total of 23 patients
above the age of 65 years were enrolled. Patients were treated
with KRd induction for eight cycles, followed by KRd maintenance for cycles 9–24 and then lenalidomide maintenance
until progression or toxicity. The ORR was 100%, with the
17 patients completing at least eight cycles of treatment, all
achieving at least an nCR and 76% reaching an sCR. One- and
2-year PFS rates were 97% and 92%, respectively.26
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High-risk cytogenetics
The role of cytogenetics in risk-stratifying prognosis for MM
patients is well documented.38,39 Chromosomal alterations
are well described, and are often complex in nature.40 These
chromosomal aberrations have varied effects on outcomes
for patients with MM.41
With the introduction of the proteasome inhibitor bortezomib, evidence of its ability to overcome the adverse impact
of some cytogenetic markers was noted.42–44 To evaluate the
efficacy of carfilzomib in the management of patients with
adverse cytogenetics, a prospective subgroup analysis of the
Phase II PX-171-003-A1 trial was performed. In this study
of 257 evaluable RRMM patients, cytogenetic profiles were
available for 229 patients, of whom 62 (27.1%) had high-risk
cytogenetics (defined as del17p13, t[4;14], t[14;16], or del13).
The remaining 167 (72.9%) had standard-risk cytogenetic
profiles, with similar baseline characteristics among the two
arms. The ORR was comparable between the groups (25.8%
versus 24.6% for high-risk and standard-risk, respectively),
with a trend of shorter response duration for high-risk
patients (median duration of response of 5.6 months versus
8.3 months). OS was significantly prolonged in the standardrisk group, with the average patient living 9.3 months with
high-risk cytogenetics and 19.0 months for standard-risk
patients. These data, particularly the equivalent response
rates, supported the efficacy of carfilzomib in overcoming
some of the impact of high-risk cytogenetic abnormalities,
but continued to show their negative effect on OS.45

Adverse effects
Given its high specificity and irreversible binding, the
side-effect profile of carfilzomib differs significantly from
bortezomib. A multitrial analysis was performed to assess
the safety profile of single-agent carfilzomib in 526 patients
with relapsed and/or refractory MM evaluating the four main
Phase II trials assessing its efficacy (PX-171-003-A0 and -A1,
PX-171-004, and PX-171-005).49 In these studies, carfilzomib
was administered on days 1, 2, 8, 9, 15 and 16 in 28-day cycles,
with the maximum dose administered being 27 mg/m2.15
The majority of patients evaluated in these trials were
heavily pretreated with a median of four prior regimens.
The most common grade 3–4 AEs were fatigue (55.5%),
anemia (46.8%), and nausea (44.9%). By organ system,
AEs were most common in the respiratory (69%), renal
(33.1%), and cardiac (22.1%) systems. Hematologic toxicities included thrombocytopenia (23.4%), anemia (22.4%),
and lymphopenia (18.1%). Febrile neutropenia was rare,
occurring in 1.1% of patients. In comparison to bortezomib,
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peripheral neuropathy was uncommon (13.9%), with no grade
4 or above reported, and all grade 3 peripheral neuropathy
occurred in those with baseline grade 1 or 2 neuropathy.46
Cardiac toxicity has been a concern with carfilzomib
since early studies. In the aggregate analysis, 38 patients
(7.2%) developed cardiac failure events (CHF, pulmonary edema, or decreased ejection fraction). There was
no difference in mortality for patients who had baseline
cardiac risk factors, and the rate of cardiac events did
not increase with subsequent cycles. Any cardiac AE
was seen in 22.1% of patients, with the most common
being: hypertension (14.3%), arrhythmia (13.3%), and
cardiomyopathy (1.7%). Complicating the evaluation of
cardiac toxicity is the nature of MM patients, who often
have multiple comorbidities and cumulative toxicities from
prior therapies. In the evaluated trials, 73.6% of patients
had a history of prior cardiac events, with 70% having
baseline cardiac risk factors.46
Accompanying cardiac events, respiratory AEs were
the most common nonhematologic organ system affected.
Dyspnea was reported in 42.2% of patients; however, most
episodes were grade 1–2, transient, and resolved without
altering dosing. Grade 3 episodes of dyspnea occurred in
only 4.8% of patients, and no grade 4 events were seen.46
Hydration has been previously recommended with carfilzomib treatment, due to concerns of acute kidney injury, and
it is suspected that some episodes of dyspnea were related to
aggressive fluid administration in the setting of significant
cardiac comorbidities.

Key ongoing studies
As described earlier, many studies have investigated the role
of carfilzomib in the RRMM setting, as well as in the newly
diagnosed patient (Table 1). Ongoing Phase I, II, and III
studies are evaluating carfilzomib as a combination agent in
the treatment of RRMM, as well as newly diagnosed disease
(Tables 2 and 3). Some of these trials have been reported and
were discussed earlier, but many are actively enrolling and
results are pending.
It seems likely that carfilzomib’s indication will grow,
with the role of combination therapies expanding and its
utility in the front-line setting evolving. Ongoing comparative Phase III trials will likely further clarify carfilzomib’s
potential benefits.
The currently enrolling ENDEAVOR trial47 is a randomized, multicenter, open-label Phase III study of carfilzomib
and dexamethasone versus bortezomib plus dexamethasone
for relapsed MM patients with no more than three prior
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Table 1 Key completed studies evaluating carfilzomib in MM
Study

Population

Patients

ORR (%)

CR + VGPR

PFS
(months)

OS
(months)

PX-171-001 (Phase I)
carfilzomib (single agent)13
PX-171-002 (Phase I)
carfilzomib (single agent)12
PX-171-003-A0 (Phase IIB)
carfilzomib (single agent)35
PX-171-003-A1 (Phase II)
carfilzomib (single agent)15
PX-171-004 (Phase II)
carfilzomib (single agent,
20 mg/m2 versus 27 mg/m2)17
PX-171-005 (Phase II)
carfilzomib (single agent)33
PX-171-006 (Phase IB)
carfilzomib + Rd22
PX-171-006 (Phase II)
carfilzomib + Rd21
PX-171-007 (Phase IB/II)
carfilzomib (single agent)
dose-expansion cohort16
Carfilzomib + Rd (Phase I/II)26
Carfilzomib + clarithromycin +
Rd (Phase I)27
FOCUS: PX-171-011 (Phase III)
carfilzomib versus best
supportive care18
ASPIRE: PX-171-009 (Phase III)
carfilzomib + lenalidomide +
dexamethasone versus
lenalidomide + dexamethasone
Planned interim analysis25

Hematologic malignancies
(MM, NHL, WM, HL)
Hematologic malignancies
(MM, NHL, HL)
RRMM

29

NR

NR

NR

NR

48

NR

NR

NR

NR

46

16.7

0 (0 + 0)

3.5

NR

RRMM

266

23.7

5.5% (0.4% + 5.1%)

3.7

15.6

RRMM

129

42.4
versus 52.2

17% (3.4% + 13.6%)
versus 28.4% (1.5% + 26.9%)

8.2
versus NR

NR

RRMM: renal
dysfunction
Relapsed or
progressive MM
Relapsed or
progressive MM
Relapsed MM, solid
tumors or lymphoma

50

25.5

0 (0 + 0)

NR

NR

40

62.5

35% (2.5% + 32.5%)

10.2

NR

52

76.9

42.2% (5.7% + 36.5%)

28.7

37

33

55

28% (5% + 23%)

7

NR

Newly diagnosed
Newly diagnosed

53
24

98
87

81% (62% + 19%)
61% (13% + 48%)

NR
NR

NR
NR

RRMM

315

NR

NR

NR

NR

Relapsed MM

792

NR

NR

26.3
versus 17.6

NR

Abbreviations: ORR, overall response rate; CR, complete response; VGPR, very good partial response; PFS, progression-free survival; OS, overall survival; RRMM, relapsed
and refractory multiple myeloma; NHL, non-Hodgkin’s lymphoma; WM, Waldenström’s macroglobulinemia; Rd, Revlimid and dexamethasone; NR, not reported.

therapies. Patients must have had at least one prior therapy
to which a response was recorded. Given carfilzomib’s
improved safety profile and increased specificity, this will
compare the outcomes and safety of bortezomib versus
carfilzomib in relapsed MM patients. The primary outcome
is PFS.
The CLARION trial is a Phase III study of carfilzomib,
melphalan, and prednisone versus bortezomib, melphalan,

and prednisone in newly diagnosed MM patients who are
ineligible for transplant. The primary outcome is PFS, with
efficacy and safety as key secondary outcomes.48

Conclusion
Significant changes in the management of MM over the past
several decades have greatly improved outcomes. Despite
many advances, MM remains an incurable disease. The

Table 2 Key ongoing trials in newly diagnosed multiple myeloma (MM)
Regimen

Population

Authors

Patients

Phase

Carfilzomib + bendamustine + dexamethasone
Carfilzomib + high-dose melphalan
Carfilzomib + melphalan + prednisone versus
bortezomib + melphalan + prednisone (CLARION)
Initial and posttransplant treatment with
carfilzomib + revlimid + dexamethasone
Carfilzomib + lenalidomide + dexamethasone

Newly diagnosed
Transplant-eligible (preparative regimen)
Transplant-ineligible, newly diagnosed

Lentzsch et al49
Costa et al50
Facon et al48

34
58
882

I/IIB
I/IIA
III

Newly diagnosed, transplant-eligible,
pre- and post-ASCT
Smoldering MM (high risk)

Jakubowiak et al51

44

II

Landgren et al52

30

II

Abbreviation: ASCT, autologous stem cell transplantation.

30
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Table 3 Key ongoing trials in relapsed or refractory multiple myeloma
Regimen

Population

Author(s)

Patients

Phase

High-dose carfilzomib for MM patients with
progression on standard dose carfilzomib
Bruton’s tyrosine-kinase inhibitor + carfilzomib in RRMM
Arry-520 + carfilzomib
Two dose levels of carfilzomib + dexamethasone
for RRMM (S1304)
Panobinostat + carfilzomib
Pomalidomide + dexamethasone + carfilzomib (PdC)
Carfilzomib + lenalidomide + vorinostat + dexamethasone
Carfilzomib + pegylated liposomal doxorubicin +
dexamethasone
60-Minute infusion of carfilzomib
Carfilzomib/SAHA + high-dose gemcitabine/busulfan/
melphalan + ASCT

RRMM

Chari et al

36

II

RRMM
RRMM
RRMM

Pharmacyclics54
Shah et al55
Ailawadhi et al56

223
76
140

I/IIB
I/II
II

RRMM
RRMM
RRMM
RRMM

Kaufman et al57
Jakubowiak et al58
Siegel et al59
Vij et al60

36
92
50
53

I
IB/II
I/II
I/II

RRMM
RRMM

Berenson et al61
Nieto62

38
75

I/II
II

53

Abbreviations: RRMM, relapsed and refractory multiple myeloma; MM, multiple myeloma; SAHA, suberoylanilide hydroxamic acid; ASCT, autologous stem cell
transplantation.

development of new drugs and novel combinations is key to
continued progress.
Current data show that carfilzomib is an active and tolerable
agent in the treatment of RRMM. Evidence for its efficacy and
safety continue to grow. Its role in the bortezomib-refractory
patient was clearly illustrated in the PX-171-003-A1 trial,
making it a viable and effective option for patients who were
previously refractory to proteasome inhibition.
While numerous Phase II trials have shown it to have
excellent response rates and a tolerable safety profile, initial
Phase III studies are just now being reported. While aggregate
results are encouraging, there continues to be much to learn
about carfilzomib’s role in the management of the newly
diagnosed patient, as well as its efficacy and tolerability as
combination therapy. Further studies will continue to clarify
the optimal dosing regimen and technique to maximize safety
and efficacy.
The role of carfilzomib in the setting of emerging oral
proteasome inhibitors remains to be seen. While patient preferences may strongly favor oral options, their comparative
efficacy and side-effect profiles are still under investigation.
It is likely there will continue to be a clear role for parenteral
proteasome inhibitors despite the advent of oral options.
Further questions yet to be answered include the role of
carfilzomib in the maintenance setting and the variable
utility of proteasome inhibitors in the era of personalized
medicine.
Overall, carfilzomib represents an excellent option for
patients with MM. We expect its indication to grow and
its regulatory approval to expand outside the US. As data
continue to accumulate supporting its efficacy and safety, it
will maintain its role as a backbone of treatment.
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